<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between June 1979 and June 1984 18 adult patients with small noncleaved cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (SNCL) (diffuse undifferentiated <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Burkitt's and non-Burkitt's types of the Rappaport classification) were treated with high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="8382">prednisone</z:chebi>, midcycle high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, and intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Early in the course of treatment, hyperfractionated radiotherapy (125 cGy, every two days, for 1,500 to 2,250 centigray [cGy]) was administered to unresected masses greater than 10 cm in their greatest dimension </plain></SENT>
<SENT sid="2" pm="."><plain>Chemotherapy was administered every 21 days for six to ten cycles </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment was generally well tolerated; however, one patient died of probable <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor lysis syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>With a median follow-up of 1.2 years, actuarial survival was 66.8% and relapse-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>) was 71.3% for the entire group </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> treatment failures and <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred in patients with stage D disease </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> projected at 2 years was 100% for stages A and AR and 60.6% for stage B, C, and D (P = .13 Gehan) </plain></SENT>
<SENT sid="7" pm="."><plain>Two-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> for patients with stage A, AR, B, or C disease was 100 v 41% for those with stage D disease </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with adverse prognostic features (n = 7)--unresected bulk measuring greater than 10 cm, pretreatment serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH) 500 IU/L (<z:mpath ids='MPATH_458'>normal</z:mpath>, 200) or involvement of <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> or bone marrow--had a projected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> of 28.6% compared with 100% for those patients without these features (P = .002 Gehan) </plain></SENT>
<SENT sid="9" pm="."><plain>Too few patients received induction radiotherapy to assert its role in therapy </plain></SENT>
<SENT sid="10" pm="."><plain>By using aggressive multiagent therapy, cure can be expected in a high percentage of adults with SNCL </plain></SENT>
<SENT sid="11" pm="."><plain>In the subset with adverse prognostic features, more effective therapy is necessary </plain></SENT>
</text></document>